Global Presence ONK Therapeutics operates in Ireland and the United States with Galway and San Diego footholds, enabling cross regional deals, clinical collaborations, and licensing opportunities across Europe and North America.

Innovative Platform The off the shelf dual targeted NK cell platform combines CAR targeting a tumor antigen with TRAILv to engage death receptor pathways, offering potential advantages against antigen escape and improved persistence for partner programs.

Market Focus Focused on hematologic malignancies and solid tumors, expanding potential collaboration avenues with pharma, CROs, and CDMOs for clinical development and trials.

Growth Leadership Recent leadership appointments and board growth in the US and Ireland indicate expanding R&D capacity and translational expertise, presenting co development and advisory partnership possibilities.

Commercial Potential Revenue is currently modest with 2023 licensing activity, signaling opportunities for milestone driven licensing deals, sponsored research, or collaboration agreements with biotechs and mid sized pharma seeking innovative NK platforms.